Matthew Matasar

32PUBLICATIONS
185CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsiesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Jul 06, 2026
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

|Mar 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma.

Geoffrey Shouse, Matthew Matasar, Lu Chen

|Feb 05, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker

|Nov 07, 2025
Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

John S Wang, Brandon L Ellsworth, Megan Melody

|Oct 22, 2025
Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Megan Melody, Natalie Grover, Stephanie Franco

|Sep 24, 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Franck Morschhauser, Gilles Salles, Laurie H Sehn

Pageof 6

Frequent Collaborators

10 joint publications

Andrew D Zelenetz

8 joint publications

Gilles Salles

8 joint publications

Connie Lee Batlevi

7 joint publications

Anita Kumar